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Clinical Valve Thrombosis and
Subclinical Leaflet Thrombosis
Following Transcatheter Aortic Valve
Replacement: Is There a Need for a
Patient-Tailored Antithrombotic
Therapy?
Liesbeth Rosseel*, Ole De Backer and Lars Søndergaard
The Heart Center, Rigshospitalet, Copenhagen, Denmark
Transcatheter aortic valve replacement (TAVR) has become an established therapeutic
option for patients with symptomatic, severe aortic valve stenosis at increased surgical
risk. Antithrombotic therapy after TAVR aims to prevent transcatheter heart valve
(THV) thrombosis, in which two different entities have to be recognized: clinical valve
thrombosis and subclinical leaflet thrombosis. In clinical valve thrombosis, obstructive
thrombus formation leads to an increased transvalvular gradient, often provoking heart
failure symptoms. Subclinical leaflet thrombosis is most often an incidental finding,
characterized by a thin layer of thrombus covering the aortic side of one or more
leaflets; it is also referred to as Hypo-Attenuating Leaflet Thickening (HALT) as described
on multi-detector computed tomography (MDCT) imaging. This phenomenon may also
affect leaflet motion and is then classified as Hypo-Attenuation affecting Motion (HAM).
Even in case of HAM, the transvalvular pressure gradient remains within normal range
and does not provoke heart failure symptoms. Whereas, clinical valve thrombosis
requires treatment, the clinical impact and need for intervention in subclinical leaflet
thrombosis is still uncertain. Oral anticoagulant therapy protects against and resolves
both clinical valve thrombosis and subclinical leaflet thrombosis; however, large-scale
randomized clinical trials studying different antithrombotic strategies after TAVR are still
under way. This review article summarizes the currently available data within the field of
transcatheter aortic valve/leaflet thrombosis and discusses the need for a patient tailored
antithrombotic approach.
Keywords: aortic valve replacement, transcatheter, clinical valve thrombosis, subclinical leaflet thrombosis,
antithrombotic therapy
INTRODUCTION
Transcatheter aortic valve replacement (TAVR) has become an established therapeutic option
for patients with symptomatic, severe aortic valve stenosis who are at increased surgical risk.
Furthermore, the NOTION trial (Nordic Aortic Valve Intervention Trial) showed that TAVR may
also be a viable option for patients with a lower risk profile (1). Antithrombotic therapy after
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TAVR aims to prevent transcatheter heart valve (THV)
thrombosis. Two different entities have to be recognized: clinical
valve thrombosis and subclinical leaflet thrombosis. This review
aims to summarize and discuss currently available data on
clinical valve thrombosis and subclinical leaflet thrombosis in
transcatheter aortic bioprosthesis with additional focus on a
patient-tailored antithrombotic approach.
DEFINITION AND INCIDENCE
Although prosthetic valve thrombosis is a well-known risk for
mechanical heart valves, this risk is much less recognized in
bioprosthetic heart valves. Following implantation of mechanical
valve prostheses, patients have to take life-long oral anticoagulant
(OAC) therapy. This is not the case for patients who receive
a surgical or transcatheter bioprosthetic heart valve, for which
long-term treatment with antiplatelet therapy (APT) seems to
be sufficient. However, despite the less thrombogenic profile
of bioprosthetic heart valves, recent studies also report the
occurrence of valve/leaflet thrombosis in different types of
transcatheter and surgical aortic bioprosthesis (2–10). Thereby, it
is important tomake the difference between two different entities:
clinical valve thrombosis and subclinical leaflet thrombosis.
Clinical valve thrombosis is defined as clinical apparent
prosthetic valve dysfunction with the typical finding of a mobile
mass/thrombus on the prosthetic heart valve as visualized
by echocardiography or multi-detector computed tomography
(MDCT). Prosthetic valve dysfunction may be provoked by
FIGURE 1 | Clinical valve thrombosis. (A,B) Transesophageal
echocardiography (TEE) showing thrombosis and turbulent color flow over a
bioprosthetic aortic valve in a patient who underwent transcatheter aortic valve
replacement 6 years earlier. The patient presented with dyspnea NYHA class
3b and echocardiography revealed a mean transvalvular gradient of 37 mmHg
(C,D) The thrombotic mass at the prosthetic leaflets was confirmed by
intracardiac echocardiography from the ascending aorta.
reduced leaflet motion or impaired leaflet coaptation caused
by thrombus, but it is important that this gets differentiated
from other causes such as valve degeneration, fibrotic pannus
ingrowth or endocarditis (Figure 1). The clinical appearance of
this phenomenon may be either symptoms of heart failure, or left
sided thrombo-embolic event.
Following surgical aortic valve replacement (SAVR) with a
bioprosthesis, the incidence of clinical valve thrombosis has been
reported to range between 0.3 and 6.0% (11–14). More recently,
this phenomenon of clinical valve thrombosis has also been
described following TAVR. Based on retrospective observational
registries, the incidence of clinical valve thrombosis in TAVR
patients is estimated to be 0.6 to 2.8% (15, 16).
Subclinical leaflet thrombosis was firstly described in a case
report in 2013, 7 days after TAVR while doing routine MDCT
imaging (17). A hypoattenuating structure in one cusp thereby
restricting normal cusp movement was described, although
a normal transvalvular pressure gradient was measured on
transthoracic echocardiography (TTE). Control CT after 10
weeks OAC treatment showed full resolution of the initial
finding. This phenomenon was than further investigated in the
combined SAVORY/RESOLVE registry, describing the existence
of leaflet thickening and reduced leaflet motion in different types
of transcatheter and surgical aortic bioprosthesis (2). Subclinical
leaflet thrombosis is described as a thin layer of thrombus that
can involve one or all three leaflets, with typical appearance
on MDCT as a hypo-attenuating defect at the aortic side of
the leaflets, also called Hypo-Attenuating Leaflet Thickening
(HALT). When leaflet motion is affected for more than 50%, this
phenomenon is classified as Hypo-attenuation Affecting Motion
(HAM) (Figure 2). As this leaflet thickening is typically an
incidental finding not causing any clinically significant valvular
dysfunction, it is called “subclinical” leaflet thrombosis.
The reported incidence of subclinical leaflet thrombosis
is likely to be influenced by the timing and the intensity
of screening as well as the applied diagnostic criteria and
imaging tools. Table 1 gives an overview of available studies
that performed prospective screening for subclinical leaflet
thrombosis. Incidence of subclinical leaflet thrombosis, with
or without reduced leaflet motion, varies between 7 and 35%
in different types of THVs (2–9). Only few studies report on
the incidence of subclinical leaflet thrombosis in surgical aortic
bioprosthesis. In the SAVORY/RESOLVE registry, the incidence
of subclinical leaflet thrombosis in surgical aortic bioprosthesis
appeared to be lower than in THVs with an incidence rate
of 4%, although SAVR patients were younger and with less
comorbidities than the TAVR population (5). Finally, in a
prospective trial investigating a sutureless type of surgical aortic
bioprosthesis, a higher incidence was reported with 38% of
patients having HALT and 28% showing HAM (10).
DIAGNOSIS
The diagnostic sequence is fundamentally different for clinical
valve thrombosis and subclinical leaflet thrombosis. As
embedded in the terminology, “clinical” valve thrombosis
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FIGURE 2 | Subclinical leaflet thrombosis. (A) Computed tomography (CT) images showing hypoattenuating leaflet thickening (HALT) at the base of all three
bioprosthetic leaflets, (B) with hypoattenuation affecting motion (HAM) visible in systole in the volume-rendered 4DCT images; and (C) transesophageal
echocardiography (TEE) confirming reduced leaflet motion of two leaflets. (D–F) Resolution of HALT and HAM after 3 months of anticoagulation treatment.
presents most of the time with clinical symptoms, whereas
“subclinical” leaflet thrombosis typically presents as an incidental
finding on MDCT or TEE imaging in asymptomatic patients.
European guidelines recommend echocardiography,
including measurement of transprosthetic gradient, at
baseline (within 30 days), at 1 year after valve implantation
and annually thereafter, and earlier if any new symptom
occurs (18). However, first-line screening with TTE for
prosthetic valve dysfunction has been reported to have
low sensitivity. Therefore, additional TEE imaging is
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recommended in case of clinical suspicion of prosthetic
valve dysfunction.
A predictive model for surgical bioprosthetic heart
valve thrombosis has been proposed, combining three
echocardiographic and two clinical predictors: (1)
presence of >50% increase in mean transvalvular
gradient, (2) increase of cusp thickness, (3) abnormal
cusp mobility, and (4) presence of paroxysmal atrial
fibrillation with (5) sub-therapeutic international
normalized ratio (INR) under warfarin therapy were
reported to be predictors of bioprosthetic valve
thrombosis (19).
In clinical valve thrombosis, symptoms of heart failure may
appear progressively or even (sub)acutely, or the diagnosis
may be made following a left-sided thromboembolic event.
In such patients with symptoms and/or a sudden increase of
transprosthetic gradient or new central aortic regurgitation, an
additional TEE should be performed to examine other causes
of THV deterioration. MDCT may be considered whenever
TEE is not sufficient for clear diagnosis. However, in two
retrospective observational studies, only a minority of TAVR
patients (26–39%) with THV dysfunction and presence of valve
thrombosis, presented with dyspnea (15, 16). This demonstrates
that diagnosis is often established based on echocardiographic
FIGURE 3 | Algorithm for the follow-up of TAVR patients. (A) Standard antithrombotic treatment and follow-up according to the European guidelines. (B) Need for
additional investigations/follow-up in case of heart failure symptoms and/or thromboembolic events. 4DCT, 4-dimensional computed tomography; DAPT, double
antiplatelet therapy; (N)OAC, (novel) oral anticoagulant; SAPT, single antiplatelet therapy; TAVR, transcatheter aortic valve replacement; TEE, transesophageal
echocardiography; THV, transcatheter heart valve; TIA, transient ischemic attack; TTE, transthoracic echocardiography.
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findings, even before symptoms appear. In these studies,
transvalvular aortic gradients were elevated–with more than 90%
of patients having a mean gradient >20 mmHg–irrespective
of the presence of symptoms, with most often appearance of
thickened leaflets or thrombotic apposition, and in a minority of
cases a visible thrombotic mass as seen by TTE (15).
The functional consequence may be isolated valvular
stenosis, a combined valvular stenosis-regurgitation, or pure
valvular regurgitation as reported for surgical bioprosthesis
(19). Accordingly, one other study involving TAVR patients
reported a significant increase of NT-proBNP levels in
patients with clinical valve thrombosis (16). In these studies,
clinical valve thrombosis was detected between 3 weeks
and 1 year after valve implantation, indicating that this
phenomenon is not only limited to the first 3 months following
AVR (15, 16).
In case of subclinical leaflet thrombosis, where patients are
asymptomatic, diagnosis is often made incidentally on cardiac
MDCT-imaging, as part of a clinical study protocol. Changes
in transvalvular gradient are more subtle and often still within
normal range (2, 4, 5). In the combined SAVORY/RESOLVE
registry, including both TAVR and SAVR patients, the mean
aortic transvalvular gradient in the HAM-group was 13.8 ±
10.0 mmHg as compared to 10.4 ± 6.3 mmHg in patients
with normal leaflet motion (5). Three studies have performed
sequential imaging over time, and all of these showed that HALT
and HAM can either remain stable, worsen or even regress over
time (8, 9, 20). Two of these studies reported that OAC protects
against progression (9, 20). Other studies did not show any
association between “time to CT” and the presence of subclinical
leaflet thrombosis (5, 6). Importantly, all studies demonstrated
that subclinical leaflet thrombosis may appear both early or
late after valve implantation, with varying evolutions of either
progression, stability or regression at different time intervals, and
diverge among different antithrombotic strategies.
TEE has shown to be equally sensitive for the detection of
leaflet thickening, thrombotic appositions, or restricted leaflet
mobility as compared to MDCT imaging (2). However, as
the clinical significance of subclinical leaflet thrombosis is not
clear, and MDCT requires exposure to radiation and contrast
agent and TEE is limited by its rather invasive character, it is
not recommended to use MDCT-imaging or TEE as a routine
post-procedure screening tool for subclinical valve thrombosis
outside clinical studies.
PREDISPOSING FACTORS
AND PATHOPHYSIOLOGY
Little is known about the complex pathophysiology of
bioprosthetic valve thrombosis and most investigations are
based on imaging studies. The difference in incidence of
TABLE 2 | Overview of completed and ongoing trials investigating different antithrombotic strategies after TAVR.
Trial Anti-thrombotic strategy Target population Study
population
Anticipated
completion
date
Outcome
Warfarin and antiplatelet therapy
vs. warfarin alone for treating
patients with atrial fibrillation
undergoing TAVR
VKA vs. VKA + single or
double APT
Patients with atrial fibrillation 621 Completed Similar rate of MACE, stroke and death; but
significantly higher rate of major or
life-threatening bleedings in VKA + APT group
(13 months FU)
ARTE
NCT01559298
ASA + clopidogrel vs.
ASA alone
Patients without need for
chronic OAC
222 Completed No differences in hemodynamics, MACE, TIA,
stroke, and death; less major or life-threatening
events in ASA alone group (3 months FU)
GALILEO
NCT02556203
Rivaroxaban 10mg + ASA
(3 months), followed by
rivaroxaban alone vs. DAPT
(3 months), followed by
ASA alone
Patients without need for
chronic OAC
1644 2018 Stopped prematurely because of increased
bleeding and mortality in the rivaroxaban group.
AUREA
NCT01642134
ASA + clopidogrel vs. VKA Patients without need for
chronic OAC
124 2019 –
POPular–TAVI
NCT02247128
ASA + clopidogrel vs. ASA
alone, or OAC + clopidogrel
vs. OAC alone
All-comers 1,000 2020 –
ATLANTIS
NCT02664649
Apixaban vs. standard of
care (VKA or SAPT/DAPT)
All-comers 1,510 2020 –
AVATAR
NCT02735902
ASA + VKA vs. VKA alone Patients with underlying
indication for chronic OAC
170 2020 –
ENVISAGE-TAVI AF
NCT02943785
VKA vs. edoxaban (both
with APT if needed)
Patients with atrial fibrillation 1,400 2020 –
ADAPT-TAVR
NCT03284827
Edoxaban vs. ASA +
clopidogrel (min. 6 months)
Patients without absolute
indication for chronic OAC
220 2020 –
APT, antiplatelet therapy; ASA, acetylsalicylic acid; DAPT, double antiplatelet therapy; FU, follow-up; MACE, major adverse cardiovascular events; OAC, oral anticoagulant; SAPT, single
antiplatelet therapy; TIA, transient ischemic attack; VKA, vitamin-K antagonist.
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prosthetic valve thrombosis for surgical and transcatheter aortic
bioprosthesis also suggests the involvement of multiple and
divergent pathophysiological mechanisms, including device
variables, host variables, and antithrombotic therapy.
Device Variables
Different devices have different valve designs, consist of different
materials and use different implantation techniques, all of which
may influence the mechanism and risk for thrombus formation.
In contrast with SAVR, the native aortic valve leaflets remain
present in TAVR and are pushed aside in the sinus of Valsalva.
This may not only cause mechanical differences with differing
valve geometry and hemodynamics, the remaining (damaged)
native valve tissue may also induce thrombosis due to exposure
of tissue factor. Besides this, contact with the artificial surface
of the bioprosthesis may promote thrombus formation through
complex cascades beginning with plasma protein absorption to
fibrinogen, subsequent platelet, leucocyte, and red cell adhesion,
thrombin generation, and complement activation (21). Pathology
studies show that the initial fibrin coat on the prosthetic surface is
replaced by neointima within∼3 months (22). However, delayed
endothelialisation, damage of leaflet tissue by THV crimping
or post-dilatation, and differences in type of leaflet tissue may
influence thrombogenicity of this surface. Moreover, one study
showed that porcine surgical bioprostheses are at higher risk for
valve thrombosis as compared to bovine tissue (23), whereas
one other study reported that residual presence of aldehydes–
a substance contained in the storage liquid for storage of these
bioprostheses–may also contribute to leaflet thrombosis in case
of insufficient cleansing (24).
TABLE 3 | Bioprosthetic valve thrombosis: clinical presentation, diagnosis, and
treatment.
Clinical valve thrombosis Subclinical leaflet
thrombosis
Clinical
presentation
Dyspnea
Heart failure symptoms
Left sided thromboembolic event
(TIA, stroke, or
peripheral embolism)
Asymptomatic
No routine screening
(MDCT, TEE)
Diagnosis TTE/TEE
Leaflet thickening
Thrombotic apposition(s)
Thrombotic mass
Increased transvalvular gradient
TEE/MDCT
Leaflet thickening
Leaflet motion impairment
Treatment If stable patient:
Initiate 6–12 week OAC
Echocardiographic follow-up
Restart (N)OAC if re-occurrence
Consider redo-AVR if no effect of
anticoagulation
If unstable patient:
Redo-AVR, if possible VIV-TAVR
Sharpened vigilance
No routine (N)OAC
Shorten echocardiographic
follow-up interval and consider
(N)OAC in case of increasing
transvalvular gradient or
thromboembolic event
AVR, aortic valve replacement; MDCT, multi-detector computed tomography; OAC, oral
anticoagulant; TEE, transesophageal echocardiography; TIA, transient ischemic attack;
TTE, transthoracic echocardiography; VIV, valve-in-valve.
Also flow dynamics differ according to valve design and
can be influenced by the potential occurrence of regional
malappositioning or underexpansion of THVs. Areas with
turbulence, such as the neo-sinuses (created after TAVR), may
lead to increased “shear stress” causing endothelial damage
and may also create sites with “low-flow,” thereby increasing
the risk of thrombosis. In addition, it has been reported
that the THV stent frame geometry may be important in
the process of subclinical leaflet thrombosis (25). Regional
underexpansion of the THV stent frame has been associated
with an increased incidence of subclinical leaflet thrombosis,
particularly for THVs with an intra-annular valve position.
The hypothesis is that, in case of THV underexpansion, the
leaflet may not completely unfold and be more prone to
thrombus formation. In one other study, intra-annular THVs
and deeper implantation of supra-annular self-expanding THVs
resulted in larger neo-sinuses and, hence, a higher risk for
leaflet thrombosis (26). Consequently, it has been suggested
that bicuspid valves may be associated with a higher risk for
leaflet thrombosis, as THVs end up more often non-circular—
hence, underexpanded—and bicuspid anatomies are sometimes
linked with a larger sinus of Valsalva. However, evidence
confirming this theoretical link is still missing. According to a
recent meta-analysis that pooled data from seven observational
studies, also here THVs with intra-annular valve design were
associated with a higher risk for leaflet thrombosis as compared
to THVs with supra-annular valve design (27). On the other
hand, an in-vitro study had generated the hypothesis that post-
dilatation may increase the risk for leaflet thrombosis because
of histologically proven tissue damage to the leaflets. However,
no clinical studies have confirmed this relation and even a lower
rate of leaflet thrombosis following post-dilatation has been
reported (25).
Host variables may potentially also predispose for device
thrombosis. Patient-specific co-morbidities that are known
to provoke a pro-thrombotic state are renal insufficiency,
diabetes mellitus, heart failure, atrial fibrillation, chronic
anemia, smoking, etc. These characteristics may also play
an important and contributing role in the incidence of
valve/leaflet thrombosis.
Finally, the chosen antithrombotic strategy after AVR has been
reported to have a major influence on the development of both
clinical valve thrombosis and subclinical leaflet thrombosis. In
two retrospective trials, a significantly lower rate of clinical valve
thrombosis was reported for TAVR patients on OAC therapy as
compared to patients on APT therapy (15, 16). Other studies also
showed a significantly lower rate of subclinical leaflet thrombosis
in patients on OAC, while it appears there is no significant
difference in its incidence for patients on single vs. double
APT (2–6).
CLINICAL CONSEQUENCES
In clinical valve thrombosis, the functional consequence
might be isolated valvular stenosis, a combined valvular
stenosis/regurgitation, or pure valvular regurgitation, leading to
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symptoms of dyspnea. These symptoms may occur progressively
over time, but in some cases, may also lead to a more (sub)acute
setting of heart failure. Another apparent risk in case of clinical
valve thrombosis is the risk for thromboembolic events, which
can present as a transient ischemic attack (TIA), stroke, or
peripheral embolism (11, 12).
In subclinical leaflet thrombosis, patients are per definition
asymptomatic. There is, however, a concern that subclinical
leaflet thrombosis might progress toward clinical valve
thrombosis, increase the risk for thromboembolic events or
impair the durability of the aortic bioprosthesis.
Regarding the association between subclinical leaflet
thrombosis and stroke/TIA, there have been reports raising
some concerns. In the SAVORY/RESOLVE registry, HAM was
associated with an increased incidence of TIA (5). However,
this finding needs to be interpreted with caution since the
status of the leaflet was not known at the moment of TIA, with
observation of long temporal separation between the clinical
event and the MDCT scan (28). Even more, studies have shown
natural temporal dynamic changes between HALT, HAM,
and normal status without changing antithrombotic regimen
(8, 9, 20). In contrast, a prospective trial including 434 TAVR
patients studied with MDCT or echocardiography did not show
any increased stroke risk at 3 years of follow-up in patients
with subclinical leaflet thrombosis. The overall stroke rate in
this latter study was 3.2%, but none of the strokes were related
with subclinical leaflet thrombosis, nor did they have differences
in valve hemodynamics (7). Accordingly, despite the fact that
subclinical leaflet thrombosis has higher incidence in TAVR as
compared to TAVR, cerebrovascular event rates at short and
mid-term follow-up are not higher after TAVR as compared to
SAVR (1, 29–31). This does not further support this suggested
link between subclinical leaflet thrombosis and an increased risk
of neurological events.
Secondly, concerns have been raised about the possible
negative impact of subclinical leaflet thrombosis on long-term
valve durability. A recent retrospective analysis showed that
absence of OAC was independently associated with an increase
in transvalvular gradient at long-term follow-up (32). However,
the fact that this phenomenon is a dynamic process makes it hard
to investigate its possible impact on long-term durability. This
assumption is not supported by mid-term data demonstrating
THV durability to be non-inferior as compared to surgical
bioprosthetic valves, although subclinical leaflet thrombosis
occurs more frequent after TAVR than after SAVR (29, 30, 33).
Finally, it is still not clear whether subclinical leaflet
thrombosis forms a substrate or is the biological precursor
of clinical valve thrombosis. In a large prospective study,
encompassing 754 TAVR patients that underwent CT-imaging,
reporting an incidence of subclinical leaflet thrombosis of
16%, there was no increase in stroke or mortality at a mean
follow-up time of 406 days for those patients with subclinical
leaflet thrombosis. However, there was a significantly higher
rate of patients that developed clinical valve thrombosis in
the leaflet thrombosis-group as compared to the non-leaflet
thrombosis-group (2.5 vs. 0.8%; P = 0.006) (34). In another
study, five out of 28 TAVR patients with subclinical leaflet
thrombosis developed obstructive valve thrombosis associated
with heart failure symptoms, while this did not occur in
the group of patients without leaflet thrombosis (3). Whether
there is a relationship between these two phenomena is not
clear for the time being, but it may influence the strategy of
follow-up and treatment in patients diagnosed with subclinical
leaflet thrombosis.
ANTITHROMBOTIC STRATEGY
As a standard therapy, both the European (EU) and American
(US) guidelines recommend DAPT for the first 3 to 6 months
following TAVR in case of no other OAC indication (18, 35). The
US guidelines also recommend to consider treatment with OAC
during the first 3 months after bioprosthetic valve implantation,
in patients at low bleeding risk (Class IIb, level of evidence
C). For patients with atrial fibrillation, US guidelines make
no specific recommendation, while EU guidelines recommend
a combination of vitamin K-antagonist (VKA) and aspirin or
thienopyridine, considering the bleeding risk of an individual
patient (Figure 3). OAC therapy has shown to prevent the
development of both clinical valve thrombosis and subclinical
leaflet thrombosis, while APT does not show this effect (2,
3, 5, 16). Accordingly, treatment with OAC seems–at least
temporarily–to restore leaflet motion in case of HAM.
Multiple ongoing trials, with or without MDCT imaging
for leaflet thrombosis, are examining different antithrombotic
strategies (Table 2). Interestingly, the randomized ARTE trial
came up with evidence supporting aspirin monotherapy above
DAPT following TAVR using the Sapien XT THV (Edwards
Lifesciences, Irvine, US). Patients in the SAPT-group experienced
fewer major and life-threatening bleedings, without increasing
the rate of stroke, MACE or death, as compared to the DAPT
group (36).Moreover, the randomizedGALILEO trial comparing
rivaroxaban plus aspirin with standard APT therapy following
TAVR was stopped prematurely during the follow-up period due
to higher rates of bleeding and death in the rivaroxaban group
(data not published yet). While waiting for results from other
ongoing trials, current data do not support OAC as a standard
regimen for all TAVR patients given the increased bleeding risks
associated with long-term OAC therapy in this often frail and
elderly patient population.
For patients with clinical valve thrombosis, two studies
reported a beneficial evolution of the transprosthetic gradients
following VKA treatment (15, 16). However, in one study relapse
occurred after stopping VKA, while this was not observed
among patients that were switched from VKA to non-VKA
oral anticoagulants (16). In case the diagnosis of clinical valve
thrombosis is confirmed, VKA therapy should be started if no
contraindication is present. Optimal type and duration of OAC in
such cases is still unclear, but it should at least be continued until
the thrombus has resolved and the valve function is restored.
Currently there is no evidence supporting prolongation of OAC
therapy after restoration of the normal valve function, although
careful clinical and echocardiographic follow-up is warranted.
In case of recurrent clinical valve thrombosis, prolongation
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of OAC therapy could be considered, however, in order to
take such decision, one should carefully consider the patient’s
bleeding risk.
Similarly, almost all patients receiving OAC for subclinical
leaflet thrombosis showed full resolution of leaflet attenuations
and restoration of normal leaflet motion (4, 5). In one
study, relapse occurred in half of the patients when OAC
was interrupted (2). Accordingly, progression from HALT to
HAM never occurred in patients on OAC, but was reported
in 13/60 (22%) patients on APT (20). In one other study
comprising 51 patients with HALT, control MDCT-scan after
a median of 86 days showed regression in all of the 22
patients on OAC, while 11 of 29 patients on APT had
progression of leaflet thickening. After a median of 91 days
after discontinuation of anticoagulation, MDCT performed in
ten patients revealed a significant increase in leaflet restriction
and thickness, indicating that treatment of this condition may
be challenging (9).
In summary, the current knowledge does not support routine
post-procedural MDCT in order to screen for subclinical
leaflet thrombosis, because of additional exposure to radiation
and contrast agent as well as the lack of evidence on the
impact of OAC therapy on long term outcomes. In case
subclinical leaflet thrombosis is detected, it may be reasonable
to shorten the echocardiographic follow-up interval and tailor
the antithrombotic therapy to each individual patient in case
of increasing transprosthetic gradient or thrombo-embolic
event (Table 3) .
CONCLUSION
Bioprosthetic valve thrombosis encompasses two different
entities: clinical valve thrombosis and subclinical leaflet
thrombosis. Patients with clinical valve thrombosis often
present with heart failure symptoms and an increase in
transprosthetic gradient, while subclinical leaflet thrombosis is
an incidental finding on post-procedural TEE and/or MDCT
imaging. Treatment with OAC is recommended for clinical
valve thrombosis, although the optimal medical treatment and
duration is not clear yet. Whether subclinical leaflet thrombosis
is associated with an increased risk for thromboembolism or
accelerated valve degeneration is still a matter of speculation.
Based on current evidence, it is not recommended to perform
routine TEE/MDCT to screen for subclinical leaflet thrombosis,
nor to treat with OAC in detected cases. However, it is
recommended to shorten the echocardiographic follow-up
interval in case of subclinical leaflet thrombosis. Ongoing and
future randomized trials are expected to contribute to a better
and more patient-tailored antithrombotic therapy following
AVR with a bioprosthetic heart valve.
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